Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
Authors:
- Adeniyi OlagunjuAOAdeniyi Olagunju
- Jacinta NwoguJNJacinta Nwogu
- Oluwasegun EniayewuOEOluwasegun Eniayewu
- Shakir AtoyebiSAShakir Atoyebi
- Alieu AmaraAAAlieu Amara
- John KpamorJKJohn Kpamor
- Oluseye BolajiOBOluseye Bolaji
- Ebunoluwa AdejuyigbeEAEbunoluwa Adejuyigbe
- Andrew OwenAOAndrew Owen
- Saye KhooSKSaye Khoo
Open Access
- 8 July 2022
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 246
Abstract
Background : A liquid chromatography tandem mass spectrometry method to quantify drugs in dried cervicovaginal secretions from flocked swabs was developed and validated using the antiretroviral efavirenz as an example. Methods: Cervicovaginal swabs (CVS) were prepared by submerging flocked swabs in efavirenz-spiked plasma matrix. Time to full saturation, weight uniformity, recovery and room temperature stability were evaluated. Chromatographic separation was on a reverse-phase C18 column by gradient elution using 1mM ammonium acetate in water/acetonitrile at 400 µL/min. Detection and quantification were on a TSQ Quantum Access triple quadrupole mass spectrometer operated in negative ionisation mode. The method was used to quantify efavirenz in CVS samples from human immunodeficiency virus (HIV)-positive women in the VADICT study (NCT03284645). A total of 98 samples (35 paired intensive CVS and DBS pharmacokinetic samples, 14 paired sparse CVS and DBS samples) from 19 participants were available for this analysis. Results: Swabs were fully saturated within 15 seconds, absorbing 128 µL of plasma matrix with coefficient of variation (%CV) below 1.3%. The method was linear with a weighting factor (1/X) in the range of 25-10000 ng/mL with inter- and intra-day precision (% CV) of 7.69-14.9%, and accuracy (% bias) of 99.1-105.3%. Mean recovery of efavirenz from CVS was 83.8% (%CV, 11.2) with no significant matrix effect. Efavirenz remained stable in swabs for at least 35 days after drying and storage at room temperature. Median (range) CVS efavirenz AUC 0-24h was 16370 ng*h/mL (5803-22088), C max was 1618 ng/mL (610-2438) at a T max of 8.0 h (8.0-12), and C min was 399 ng/mL (110-981). Efavirenz CVS:plasma AUC 0-24h ratio was 0.41 (0.20-0.59). Conclusions: Further application of this method will improve our understanding of the pharmacology of other therapeutics in the female genital tract, including in low- and middle-income countries.Keywords
Funding Information
- Wellcome Trust (204776)
This publication has 25 references indexed in Scilit:
- Pharmacology of Antiretrovirals in the Female Genital Tract for HIV PreventionThe Journal of Clinical Pharmacology, 2018
- Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyClinical Pharmacokinetics, 2015
- Vaginal drug distribution modelingAdvanced Drug Delivery Reviews, 2015
- Short Communication: Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital TractAIDS Research and Human Retroviruses, 2014
- Population Pharmacokinetic Model of Vaginal Tenofovir 1% Gel in the Cervicovaginal FluidAIDS Research and Human Retroviruses, 2014
- Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic–tandem mass spectrometric (LC–MS/MS) analysisJournal of Pharmaceutical and Biomedical Analysis, 2014
- Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal WomenClinical Pharmacokinetics, 2012
- Antiretroviral Drug Concentrations and HIV RNA in the Genital Tract of HIV-Infected Women Receiving Long-Term Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2008
- Correlates of Mother‐to‐Child Human Immunodeficiency Virus Type 1 (HIV‐1) Transmission: Association with Maternal Plasma HIV‐1 RNA Load, Genital HIV‐1 DNA Shedding, and Breast InfectionsThe Journal of Infectious Diseases, 2001
- Volumetric self-sampling of cervicovaginal fluid: a new approach to ovulation timingFertility and Sterility, 1983